Indaptus Therapeutics, Inc.
INDPNASDAQ
Healthcare
Biotechnology
$1.57
-0.13(-7.4%)
52W $1.55 – $14.28
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products.
$3MMkt Cap
—Rev TTM
-$17MNI TTM
-0.2xP/E TTM
Latest Earnings
10-Q
Q3 FY2025Nov 11, 202510-Q for Q3 FY2025 was filed on 2025-11-12. AI summary is not available yet.
What Changed Recently
Fundamentals
How The Business Makes Money
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
Industry Biotechnology
Company Profile
CIK0001857044
ISINUS45339J2042
CUSIP45339J204
Phone347 480 9760
Address3 Columbus Circle, New York City, NY, 10019, US
SEC EDGAR